Breast cancer liquid biopsy looks for tumor cells in a liquid blood sample taken from the target cancerous site. In general, this biopsy procedure aids in the early identification of cancerous biomarkers to aid in better treatments and healthcare services. The market for liquid biopsies of breast cancer will grow at a healthy CAGR of 19.2%, from $124.46 million in 2021 to $604.71 million by 2030.

Key Industry Drivers

Globally, the number of women detected with breast cancer has increased over the past few years. Aside from this, the market will experience significant growth due to rising awareness of cancer and patient preference for non-invasive medical procedures.

Around the world, both developed and developing country governments are taking steps to support the creation of effective treatment options for various cancer types. Consequently, they are funding research projects related to various cancer types. These factors will fuel the market for liquid biopsy tests for breast cancer worldwide. Aside from this, the market will grow with a rise in technological advancements and a renewed focus on personalized medicine in the healthcare sector.

Restraining factors

The development of the market is severely constrained by the lack of accessibility to and awareness of breast cancer in underdeveloped nations. Additionally, there is a shortage of qualified professionals, and late-stage diagnosis occurs occasionally.

Key market opportunities

The use of liquid biopsy has been expanded due to the development of novel techniques, which have improved a number of aspects of breast cancer management, including early diagnosis and screening, early relapse detection, prognosis prediction, serial sampling, and effective longitudinal monitoring of disease treatment and progression response. To capture the entire genomic landscape of breast tumors, traditional cancer detection techniques like tissue biopsies fall short.

The market for breast cancer liquid biopsy will be stimulated by more regulatory approvals from governmental bodies around the world. Additionally, liquid biopsy is a clinically useful alternative to traditional methods for the detection of breast cancer. According to a survey, patients with detectable circulating tumor cells in their blood samples have a low risk of developing breast cancer again after receiving a liquid biopsy. All of these elements can support numerous future opportunities for market expansion.

Segmentation analysis

Indicator Insights

In 2021, the segment for circulating cell-free DNA (cfDNA) accounted for the largest revenue share. The ability of cfDNA to diagnose recurrence or progression, detect developing genomic abnormalities linked to drug resistance, and track tumor molecular profiling in real-time at various time points are credited with the technology’s market leadership. Many companies offer cfDNA-based goods for use in academic research. Multiple cfDNA-based cancer detection tests are currently being developed.

Application Insights

Due to the requirement for early treatment, the treatment selection segment had the largest market share in 2021. The importance of early detection, management, and characterization of breast cancer in its early stages has increased due to the development of liquid biopsies, making this clinical setting the most suitable to improve the likelihood of effective treatment selection and improved prognosis.

Over the forecast period, the diagnosis segment is anticipated to experience profitable growth. The growth is attributed to liquid biopsy’s rising dominance in the field of a cancer diagnosis. Clinical oncology has undergone a significant transformation thanks to liquid biopsy, which makes tumor monitoring and continuous tumor sampling easier and improves early cancer detection.

Regional Insights

The breast cancer liquid biopsy market was ruled by North America in 2021. Rapid technological development, the use of liquid biopsies in treatment decision-making, and expanding government initiatives can all be credited for the dominance. Due to higher investments and the presence of numerous biotechnology companies developing the tests, the U.S. dominates the North American market.

Over the forecast period, Asia Pacific will experience profitable growth. The population is expanding, there is a growing demand for services, and more businesses are entering the market, all of which are contributing to the growth.

Key Players analysis

• Biocept Inc
• Qiagen
• Bio-Rad Laboratories
• Adaptive Biotechnologies
• Epic Sciences
• Janssen Diagnostics
• Johnson & Johnson (Janssen Diagnostics)
• F. Hoffmann-La Roche Ltd
• Biodesix
• Illumina Inc.
• Guardant Health Inc.
• Myriad Genetics
• Fluxion Biosciences Inc.
•